• Je něco špatně v tomto záznamu ?

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial

C. Sarkozy, M. Trneny, L. Xerri, N. Wickham, P. Feugier, S. Leppa, P. Brice, P. Soubeyran, M. Gomes Da Silva, C. Mounier, F. Offner, J. Dupuis, D. Caballero, D. Canioni, M. Paula, R. Delarue, P. Zachee, J. Seymour, G. Salles, H. Tilly,

. 2016 ; 34 (22) : 2575-82. [pub] 20160613

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031660

PURPOSE: To study the outcome of histologic transformation (HT) in a large prospective cohort of patients with follicular lymphoma (FL) who previously responded to immunochemotherapy. PATIENTS AND METHODS: After a median 6-year follow-up of 1,018 randomly assigned patients from the PRIMA trial, disease progression was observed in 463 patients, 194 of whom had histologic documentation. RESULTS: Forty patients had histology consistent with HT, and 154 had untransformed FL (median time to recurrence, 9.6 v 22.8 months, respectively; P = .018). Thirty-seven percent of biopsies performed during the first year of follow-up showed HT corresponding to 58% of all HTs. Altered performance status, anemia, high lactate dehydrogenase level, "B" symptoms, histologic grade 3a, and high Follicular Lymphoma International Prognostic Index scores at diagnosis were identified as HT risk factors. Response (complete v partial) to immunochemotherapy or rituximab maintenance had no impact on the risk of HT. After salvage treatment, patients with HT had less frequent complete response (50.3% v 67.4%; P = .03) and more disease progression (28.2% v 9.6%; P < .001) than patients without HT. Estimated overall survival for the patients with HT was poorer (median, 3.8 v 6.4 years; hazard ratio, 3.9; 95% CI, 2.2 to 6.9). Autologous stem cell transplantation improved the outcomes of patients with HT (median overall survival, not reached v 1.7 years) but not of patients with persistent FL histology. CONCLUSION: HT in patients with FL who previously responded to immunochemotherapy is an early event associated with a poor outcome that may deserve intensive salvage with autologous stem cell transplantation. These data emphasize the necessity for biopsy at the first recurrence of FL.

Christiane Mounier Institut de Cancérologie Lucien Neuwirth Saint Priest

Clémentine Sarkozy and Gilles Salles Hospices Civils de Lyon Centre Hospitalier Lyon Sud Service d'Hématologie Pierre Bénite and Université Claude Bernard Faculté de Médecine Lyon Sud Charles Mérieux Pierre Bénite

Danielle Canioni Assistance Publique Hôpitaux de Paris Hôpital Universitaire Necker Enfants Malades

Dolores Caballero Universitario de Salamanca Salamanca Spain

Fritz Offner Gent University Gent

Hervé Tilly Université de Rouen Rouen France

Jehan Dupuis Henri Mondor University Hospital Créteil

John Seymour Peter MacCallum Cancer Centre and University of Melbourne Melbourne Australia

Luc Xerri Aix Marseille University and Institut Paoli Calmettes Marseille

Marek Trneny Charles University General Hospital Prague Czech Republic

Maria Gomes Da Silva Instituto Português de Oncologia de Lisboa Lisbon Portugal

Marlton Paula Princess Alexandra Hospital University of Queensland School of Medicine Brisbane

Nick Wickham University of Adelaide Adelaide

Pauline Brice Hôpital Saint Louis APHP and Université Paris VII

Pierre Feugier Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine Nancy

Pierre Soubeyran Institut Bergonié and Université Victor Segalen Bordeaux Bordeaux

Pierre Zachee ZNA Stuivenberg Antwerp Belgium

Richard Delarue APHP Hôpital Universitaire Necker Enfants Malades and Descartes Sorbonne Paris Cité University Paris

Sirpa Leppa Helsinki University Hospital Cancer Center and University of Helsinki Helsinki Finland

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031660
003      
CZ-PrNML
005      
20171025123110.0
007      
ta
008      
171025s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.2015.65.7163 $2 doi
035    __
$a (PubMed)27298402
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sarkozy, Clémentine $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
245    10
$a Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial / $c C. Sarkozy, M. Trneny, L. Xerri, N. Wickham, P. Feugier, S. Leppa, P. Brice, P. Soubeyran, M. Gomes Da Silva, C. Mounier, F. Offner, J. Dupuis, D. Caballero, D. Canioni, M. Paula, R. Delarue, P. Zachee, J. Seymour, G. Salles, H. Tilly,
520    9_
$a PURPOSE: To study the outcome of histologic transformation (HT) in a large prospective cohort of patients with follicular lymphoma (FL) who previously responded to immunochemotherapy. PATIENTS AND METHODS: After a median 6-year follow-up of 1,018 randomly assigned patients from the PRIMA trial, disease progression was observed in 463 patients, 194 of whom had histologic documentation. RESULTS: Forty patients had histology consistent with HT, and 154 had untransformed FL (median time to recurrence, 9.6 v 22.8 months, respectively; P = .018). Thirty-seven percent of biopsies performed during the first year of follow-up showed HT corresponding to 58% of all HTs. Altered performance status, anemia, high lactate dehydrogenase level, "B" symptoms, histologic grade 3a, and high Follicular Lymphoma International Prognostic Index scores at diagnosis were identified as HT risk factors. Response (complete v partial) to immunochemotherapy or rituximab maintenance had no impact on the risk of HT. After salvage treatment, patients with HT had less frequent complete response (50.3% v 67.4%; P = .03) and more disease progression (28.2% v 9.6%; P < .001) than patients without HT. Estimated overall survival for the patients with HT was poorer (median, 3.8 v 6.4 years; hazard ratio, 3.9; 95% CI, 2.2 to 6.9). Autologous stem cell transplantation improved the outcomes of patients with HT (median overall survival, not reached v 1.7 years) but not of patients with persistent FL histology. CONCLUSION: HT in patients with FL who previously responded to immunochemotherapy is an early event associated with a poor outcome that may deserve intensive salvage with autologous stem cell transplantation. These data emphasize the necessity for biopsy at the first recurrence of FL.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a biopsie $7 D001706
650    _2
$a kohortové studie $7 D015331
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a folikulární lymfom $x farmakoterapie $x patologie $x terapie $7 D008224
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a prospektivní studie $7 D011446
650    _2
$a rizikové faktory $7 D012307
650    _2
$a rituximab $x terapeutické užití $7 D000069283
650    _2
$a záchranná terapie $7 D016879
650    _2
$a transplantace kmenových buněk $7 D033581
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Trneny, Marek $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Xerri, Luc $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Wickham, Nick $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Feugier, Pierre $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Leppa, Sirpa $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Brice, Pauline $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Soubeyran, Pierre $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Gomes Da Silva, Maria $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Mounier, Christiane $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Offner, Fritz $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Dupuis, Jehan $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Caballero, Dolores $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Canioni, Danielle $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Paula, Marlton $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Delarue, Richard $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Zachee, Pierre $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Seymour, John $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
700    1_
$a Salles, Gilles $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain. gilles.salles@chu-lyon.fr.
700    1_
$a Tilly, Hervé $u Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.
773    0_
$w MED00002596 $t Journal of clinical oncology official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 34, č. 22 (2016), s. 2575-82
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27298402 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025123151 $b ABA008
999    __
$a ok $b bmc $g 1255253 $s 992687
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 34 $c 22 $d 2575-82 $e 20160613 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace